Literature DB >> 27050666

The refusal of the Society to accept antibiotic toxicity: missing opportunities for therapy of severe infections.

J M Rolain1, F Baquero2.   

Abstract

Over the last decade the emergence and spread of antibiotic resistance in bacteria has led to a new fear in the scientific and medical communities as well as among members of the general public. Due to the lack of development of new antibiotics, there is a need to reconsider old drugs or dosages rejected because of their toxicity. As a society, if we tolerate the potential toxicity of other drugs, such as anticancer drugs, why do we refuse to accept the use of toxic but effective antibiotics in life-threatening infections? The aim of this review is to provide insight into the reasons why the medical community remains unjustifiably unwilling to accept the risk of toxicity and the adverse effects of antibiotics that, nonetheless, might be required to treat severe infections, including those due to multidrug-resistant bacteria.
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; drugs; infections; multidrug resistance; toxicity

Mesh:

Substances:

Year:  2016        PMID: 27050666     DOI: 10.1016/j.cmi.2016.03.026

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  9 in total

Review 1.  Antimicrobial blue light: A 'Magic Bullet' for the 21st century and beyond?

Authors:  Leon G Leanse; Carolina Dos Anjos; Sana Mushtaq; Tianhong Dai
Journal:  Adv Drug Deliv Rev       Date:  2021-11-18       Impact factor: 15.470

2.  Fatal Pandoraea nosoerga infection after combined liver-lung transplantation for cystic fibrosis: a recontamination by the pre-transplantation strain.

Authors:  Lucie Peyclit; Sophie Alexandra Baron; Martine Reynaud-Gaubert; Nadim Cassir; Jean-Marc Rolain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-08       Impact factor: 3.267

Review 3.  Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria.

Authors:  Lucie Peyclit; Sophie Alexandra Baron; Jean-Marc Rolain
Journal:  Front Cell Infect Microbiol       Date:  2019-06-11       Impact factor: 5.293

4.  Antibiotic Killing of Diversely Generated Populations of Nonreplicating Bacteria.

Authors:  Ingrid C McCall; Nilang Shah; Adithi Govindan; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 5.  Host Defence Peptides: A Potent Alternative to Combat Antimicrobial Resistance in the Era of the COVID-19 Pandemic.

Authors:  Waqas Ali; Ahmad Elsahn; Darren S J Ting; Harminder S Dua; Imran Mohammed
Journal:  Antibiotics (Basel)       Date:  2022-04-01

Review 6.  Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi.

Authors:  Lucie Peyclit; Hanane Yousfi; Jean-Marc Rolain; Fadi Bittar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-20

7.  Is there a terrible issue with bacterial resistance: pro-con.

Authors:  D Raoult; M Paul
Journal:  Clin Microbiol Infect       Date:  2016-03-26       Impact factor: 8.067

Review 8.  Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections.

Authors:  Isabelle Bekeredjian-Ding
Journal:  Front Immunol       Date:  2020-08-05       Impact factor: 7.561

9.  In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria.

Authors:  Lucie Peyclit; Sophie Alexandra Baron; Linda Hadjadj; Jean-Marc Rolain
Journal:  Antibiotics (Basel)       Date:  2022-02-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.